Nature Chemical BiologyBiochemistryPeer-reviewed journal article
A Cell-Permeable Nanobody to Restore F508del Cystic Fibrosis Transmembrane Conductance Regulator Activity
Luise FranziD, Tihomir RubiliD, Anita BalázsiD, Marie OvertusiD, Kristin Kemnitz‐Hassanin, Cédric GovaertsiD, Marcus Alexander MalliD, Christian P. R. HackenbergeriD
Abstract
Nanobodies have gained considerable attention as particularly promising biopharmaceuticals. However, nanobody-based modalities are currently limited to extracellular targets due to a lack of efficient delivery methods required to reach targets inside cells. In this study, we introduce cell-permeable nanobodies for targeting a disease-relevant intracellular protein, namely the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel with the most common cystic fibrosis (CF)-causing mutation F508del. We employ cell-penetrating peptides (CPPs) to deliver a CFTR-binding nanobody (NB1) that stabilizes misfolded F508del-CFTR and prevents its degradation to restore its function. Our data show that conjugation of a disulfide-linked CPP in combination with a cell-surface anchored CPP-additive enables intracellular delivery of NB1 into CF bronchial epithelial cells, which promotes maturation and trafficking of F508del-CFTR protein to the apical cell membrane. Furthermore, we demonstrate that the cell-permeable nanobody restores CFTR chloride channel function, which can be further enhanced by the clinically approved small molecule CFTR potentiator ivacaftor. This study highlights the use of cell-permeable nanobodies for modulation of protein function and illustrates their therapeutic potential as next-generation biopharmaceuticals for intracellular delivery and targeting. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=122 SRC="FIGDIR/small/591242v1_ufig1.gif" ALT="Figure 1"> View larger version (53K): org.highwire.dtl.DTLVardef@45d357org.highwire.dtl.DTLVardef@362e56org.highwire.dtl.DTLVardef@11c4dc2org.highwire.dtl.DTLVardef@13512b1_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: protein structure
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 6
- FWCI
- 20.42
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Correcting mutant CFTR with a stabilizing nanobody reveals a novel active conformation of the channel
Marie Overtus, James N. Charlick, … Cédric Govaerts·bioRxiv·Oct 8, 2025
- In vivo correction of cystic fibrosis mediated by PNA nanoparticles
A. S. Piotrowski-Daspit, C. Barone, … M. E. Egan·bioRxiv·Jan 28, 2022
- Functional rescue of F508del-CFTR through revertant mutations introduced by CRISPR base editing
Irene Carrozzo, Giulia Maule, … Anna Cereseto·Molecular TherapyPeer-reviewed·Jan 9, 2025
- The ΔF508 CFTR defect: molecular mechanism of suppressor mutation V510D and the contribution of transmembrane helix unraveling
K. S. Simon, K. Nagarajan, … G. D. Hurlbut·bioRxiv·Apr 19, 2020
- PP-2, a src-kinase inhibitor, is a potential corrector for F508del-CFTR in cystic fibrosis
Yunguan Wang, Kavisha Arora, … Anil Goud Jegga·bioRxiv·Mar 24, 2018
- Molecular prosthetics for CFTR designed for anion selectivity outperform amphotericin B in cultured cystic fibrosis airway epithelia
Jonnathan P. Marin-Toledo, Daniel M. Greenan, … Martin D. Burke·bioRxiv·Aug 28, 2025